CND Life Sciences

United States
Scottsdale, Arizona, United States

Company profile

CND Life Sciences company profile

CND Life Sciences provides a diagnostic test and associated services that enable clinicians to detect, visualize, and quantify the phosphorylated form of alpha-synuclein in cutaneous nerve fibers. Its core offering—the Syn-One Test- leverages a minimally invasive skin-biopsy procedure to assist in the diagnostic evaluation of synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. The company also offers laboratory services that apply immunofluorescence and intraepidermal nerve fibre density assessment to support clinical decision-making in neurodegenerative and autonomic disorders. In addition, it collaborates with biopharmaceutical organisations to support clinical trials through biomarker services and longitudinal assessment of nerve-based pathology.

Business identity

Phone number
480-569-2900
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2017-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
11
Total equity funding
$31.6M
Last funding
Grant / $3M / 2025-10-22
Last equity funding
Series A / $13.5M
Investors
16
Lead investors
6
Founders
3
Articles
80

Founders and investors

Founders

Christopher GibbonsRoy FreemanTodd Dylan Levine

Lead investors

Cambrian Capital PartnersMichael J. Fox FoundationNational Institute of Neurological Disorders and StrokeNational Institute on AgingNational Institutes of HealthPeter Harris

Investors

BlueStone Venture PartnersLabCorpMBX CapitalMichael J. Fox FoundationNational Institutes of Health